» Articles » PMID: 19500466

Autologous Bone Marrow Cell Transplantation Increases Leg Perfusion and Reduces Amputations in Patients with Advanced Critical Limb Ischemia Due to Peripheral Artery Disease

Overview
Journal Cell Transplant
Date 2009 Jun 9
PMID 19500466
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Bone marrow cell transplantation has been shown to induce angiogenesis and thus improve ischemic artery disease. This study evaluates the effects of intramuscular bone marrow cell transplantation in patients with limb-threatening critical limb ischemia with a very high risk for major amputation. After failed or impossible operative and/or interventional revascularization and after unsuccessful maximum conservative therapy, 51 patients with impending major amputation due to severe critical limb ischemia had autologous bone marrow cells (BMC) transplanted into the ischemic leg. Patients 1-12 received Ficoll-isolated bone marrow mononuclear cells (total cell number 1.1 +/- 1.1 x 10(9)), patients 13-51 received point of care isolated bone marrow total nucleated cells (3.0 +/- 1.7 x 10(9)). Limb salvage was 59% at 6 months and 53% at last follow-up (mean 411 +/- 261 days, range 175-1186). Perfusion measured with ankle-brachial index (ABI) and transcutaneous oxygen tension (tcpO(2)) at baseline and after 6 months increased in patients with consecutive limb salvage (ABI 0.33 +/- 0.18 to 0.46 +/- 0.15, tcpO(2) 12 +/- 12 to 25 +/- 15 mmHg) and did not change in patients eventually undergoing major amputation. No difference in clinical outcome between the isolation methods were seen. Clinically most important, patients with limb salvage improved from a mean Rutherford category of 4.9 at baseline to 3.3 at 6 months (p = 0.0001). Analgesics consumption was reduced by 62%. Total walking distance improved in nonamputees from zero to 40 m. Three severe periprocedural adverse events resolved without sequelae, and no unexpected long-term adverse events occurred. In no-option patients with end-stage critical limb ischemia due to peripheral artery disease, bone marrow cell transplantation is a safe procedure that can improve leg perfusion sufficiently to reduce major amputations and permit durable limb salvage.

Citing Articles

The future of diabetic wound healing: unveiling the potential of mesenchymal stem cell and exosomes therapy.

Memarpour S, Raoufinia R, Saburi E, Razavi M, Attaran M, Fakoor F Am J Stem Cells. 2024; 13(2):87-100.

PMID: 38765803 PMC: 11101987. DOI: 10.62347/OVBK9820.


Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review.

Hetta H, Elsaghir A, Sijercic V, Akhtar M, Gad S, Moses A Health Sci Rep. 2024; 7(4):e2036.

PMID: 38650719 PMC: 11033295. DOI: 10.1002/hsr2.2036.


Mesenchymal Stem/Stromal Cells for Therapeutic Angiogenesis.

Yusoff F, Higashi Y Cells. 2023; 12(17).

PMID: 37681894 PMC: 10486439. DOI: 10.3390/cells12172162.


Label extension, single-arm, phase III study shows efficacy and safety of stempeucel® in patients with critical limb ischemia due to atherosclerotic peripheral arterial disease.

Gupta P, Shivashankar P, Rajkumar M, Mahapatra S, Desai S, Dhar A Stem Cell Res Ther. 2023; 14(1):60.

PMID: 37005673 PMC: 10068167. DOI: 10.1186/s13287-023-03292-w.


Modalities to Deliver Cell Therapy for Treatment of Chronic Limb Threatening Ischemia.

Setia O, Lee S, Dardik A Adv Wound Care (New Rochelle). 2023; 13(5):253-279.

PMID: 37002893 PMC: 11305013. DOI: 10.1089/wound.2022.0114.